Cargando…
FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next?
Patients with intrahepatic cholangiocarcinoma (iCCA) face a highly dismal prognosis, due to late stage diagnosis, the relative chemoresistance of the disease, and an overall limited portfolio of established therapeutic concepts. In recent years, a number of next generation sequencing studies have pr...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498964/ https://www.ncbi.nlm.nih.gov/pubmed/32983265 http://dx.doi.org/10.1177/1758835920953293 |